In fact, immune checkpoint inhibitors targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and CTLA-4 (both of which suppress T-cell proliferation) have shown unprecedented, sustained responses in certain tumor types. The gene discussed is CTLA4; the disease is neoplasm.